|
|
 |
|
|
|
Iwao Ojima
Distinguished Professor
Director, Institute of Chemical Biology and Drug Discovery
B.S., 1968, M.S., 1970, Ph.D., 1973, University of Tokyo. Senior Research Fellow and Group Leader, 1973-1983, Sagami Institute for Chemical Research. Associate Professor (1983), Professor (1984), Leading Professor (1991), Distinguished Professor (1995), Department of Chemistry, State University of New York at Stony Brook.
Tel: (631) 632-7890
Fax: (631) 632-7942
Email: iojima@notes.cc.sunysb.edu
Publications |
|
Awards and Honors: Emmanuel B. Herschberg Award, the American Chemical Society, 2001. The Chemical Society of Japan Award for Distinguished Achievements, 1999. American Chemical Society Arthur C. Cope Scholar Award , 1994. . The Chemical Society of Japan 25th National Young Investigator Award, 1976. Fellow, New York Academy of Sciences, 2000. Fellow, American Association for the Advancement of Science, 1997. Fellow, John S. Guggenheim Foundation, 1995. William and Florence Catacosinos Professor in Cancer Research, 1994. Distinguished Professorship, State University of New York, 1995. Leading Professorship, State University of New York at Stony Brook, 1991. Dr. H. Martin Friedman University Lecturer, Rutgers University, 2001. Weissberger-Williams Lecturer, Eastman Kodak Co., 1997. Boehringer-Ingelheim Distinguished Lecturer, Colorado State University, 1997. George Lesher Lecturer, Rensselaer Polytechnic Institute, 1995. J. Clarence Karcher Lecturer, The University of Oklahoma, 1992. National Science Council Lecturer, Taiwan, 1990. Eli Lilly Lecturer, University of Kansas-Lawrence, 1990. Editorial Advisory Board of Journal of Organic Chemistry (ACS) (1995-1999). Editorial Advisory Board of Organometallics (ACS) (1996-1998). Editorial Board of Journal of Molecular Catalysis (1986-1995). Advisory Committee/Panel Reviewer: NIH, NSF, DOE. Chairman, Department of Chemistry, State University of New York at Stony Brook (1997-2003), Director, Institute of Chemical Biology & Drug Discovery (2003-present) |
|
|
SYNTHETIC, ORGANOMETALLIC, AND MEDICINAL CHEMISTRY
Design, Synthesis, and Structure-Activity Relationship Study of Biologically Active Compounds of Medicinal Interest: Discovery and development of new and potent taxoid anticancer agents, anti-thrombotic agents, cardiovascular agents, various enzyme inhibitors are our major focus in collaboration with oncologists, pharmacologists, cell biologists, hematologists, and toxicologists. These agents are being designed based on molecular modeling, synthesized by using new and efficient organic syntheses, and evaluated for their potency. results are fed back in to generate newer and better designs. Research is performed in collaboration with oncologists, pharmacologists, cell biologists, hematologists and toxicologists. We have been developing a variety of methods for the syntheses of these agents, e.g., extremely effective asymmetric synthesis of nonprotein amino acids, peptides, peptide mimetics, and taxoids using the b-Lactam Synthon Method.
Asymmetric Synthesis: We have been exploring new methodologies and reagents for asymmetric synthesis, hydrocarbonylation, reduction, etc. These methods provide the basis for the efficient syntheses of biologically active substances of medicinal interest. Mechanisms of these reactions are also studied based on spectroscopic methods including 2D NMR techniques, computer-assisted molecular modeling, and X-ray crystallography.
Homogeneous Catalysis of Transition Metal Complexes and Its Applications to Organic Syntheses: We have been developing new carbonylations of alkynes, alkenes, alkenynes, etc. We have discovered silylformylation of alkynes and silylcarbocyclizations (SiCaCs) of alkenynes and dialkynes, which are catalyzed by Rh and Rh-Co clusters or bimetallic complexes. The products of these reactions provide various versatile synthetic building blocks for alkaloids, terpenes, steroids, fluoroamino acids, etc. We are also looking into the mechanism of these catalytic reactions based on organometallic chemistry. These catalytic reactions have a high potential as future industrial processes.
Visit Professor Ojima's Home Page and the Ojima Group Home Page |
|
|
|
